Haemonetics Acquisition of Vivasure Boosts Orchestra BioMed's Finances with $21M Cash Proceeds

Haemonetics Corporation has acquired Vivasure, an Irish company specializing in percutaneous vessel closure technology, for up to $21 million in cash proceeds for Orchestra BioMed Holdings. The acquisition boosts Haemonetics' strategic position in the medical devices sector and enhances its financial health, with expanding operating margins and robust revenue growth.